Clinical trial

DETECT III - A Multicenter, Phase III Study to Compare Standard Therapy +/- Lapatinib in HER2-ve MBC-Patients With HER2+ve CTCs

NCT01619111

Study summary

ClinicalTrials.gov

DETECT III - A Multicenter, Phase III Study to Compare Standard Therapy +/- Lapatinib in HER2-ve MBC-Patients With HER2+ve CTCs

Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE3

Loading study purpose, treatment groups and outcomes…

View the complete registry record, eligibility and contacts at ClinicalTrials.gov

Drugs and interventions used in this trial

2 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

DRUG · Unmapped registry intervention standard chemo- or endocrine therapy Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention standard chemo- or endocrine therapy + Lapatinib Find medicine records · Find other trials using this name

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2012-02-01

PhasePHASE3

Conditions

HER2-negative Metastatic Breast Cancerunresolved

HER2-positive Circulating Tumor Cellsunresolved

Interventions

standard chemo- or endocrine therapyDRUG

standard chemo- or endocrine therapy + LapatinibDRUG

Sponsors & collaborators

Prof. Wolfgang Jannilead sponsor

Mapped research locations

UlmBaden-Wurttemberg, Germany1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT01619111 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.